Navigation Links
Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
Date:3/5/2008

Preclinical profile and potential for lower cardiac toxicity drives

investigator interest

SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that its investigational drug pixantrone will be studied in a multicenter phase I/II trial initiated by the Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been approved by the U.S. Food and Drug Administration (FDA) for the reduction of neurological disability and/or frequency of clinical response in patients with SP MS. A phase III trial with pixantrone in relapsed aggressive non-Hodgkin's lymphoma (NHL) is near completion.

"Despite the availability of newer biologic agents, drugs such as mitoxantrone remain an important therapy in relapsing MS. Long term cardiotoxicity remains a major drawback to treating multiple sclerosis with mitoxantrone and imposes a limitation both for selection of patients and for the duration of the treatment," said R.E. Gonsette, M.D., Chairman Fondation Charcot Stichting and principal investigator of the study. "In addition to the potential for lower cardiac toxicity, preclinical studies suggest that pixantrone may provide more effective immune regulation than mitoxantrone, the only currently approved cytotoxic agent for treating MS."

The investigator-sponsored trial (IST) will enroll 20 patients in Belgium, France and Germany.

About the Study

Twenty patients with aggressive RR MS or SP MS who failed to respond to approved immunomodulatory agents (interferons, glatiramer acetate) will be included. The objectives of the study are to determine the
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Research explores ... outcomes research also   to   be presented ... SHPG ), the global specialty biopharmaceutical company, announces that ... at the American Psychiatric Association (APA) 166th Annual Meeting ... The data being presented represent Shire,s ongoing commitment to ...
(Date:5/17/2013)... /PRNewswire-iReach/ -- The escalation of new biological drugs, ... emphasis on alternate delivery technologies. Alternate delivery technologies ... factors are converging to create both risk ... device partners . These include new classes of ... toward self-administration for chronic diseases, shifting patient demographics ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
(Date:5/18/2013)... -- Children who swallow high-powered magnets often need surgery ... to a new study. The researchers, from the ... that more than 79 percent of children who swallowed ... endoscopic procedure, in which a tube containing a camera ... of these cases can be treated through observation or ...
(Date:5/18/2013)... published an original art book for iPad with tango as ... who share their creations based on the traditional music genre ... iPad . , This work gathers more than 150 ... signature idiosyncrasy and passion of tango. Such book is ... it includes a free trailer of the book for readers ...
(Date:5/18/2013)... 2013) There are significant cost and risk ... diagnose or treat gastrointestinal problems, according to research ... A study by New York Presbyterian Hospital and ... may substantially reduce the cost and risk of ... believed to affect nearly 25 percent of adults, ...
(Date:5/18/2013)... May 18, 2013 In a May ... Preventive Double Mastectomy After Discovering Cancer Gene,” Fox News ... procedure upon learning that she carried a gene that ... breast cancer and a 50 percent risk of ovarian ... up on May 16, 2013 with a blog post ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
Breaking Medicine News(10 mins):Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New Art Book for iPad: Tango Art 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4
... A resource for medical educators interested improving their teaching ... advancing their careers in medical education is now available ... Teaching Medicine series is the first of its kind," ... summarizes the important literature of medical education and shares ...
... Health Care is undertaking an electronic medical record integration ... project is a multi-year, multi-entity corporate initiative to implement ... variability in processes and workflows across the system. Currently ... the next four years, the way UMass Memorial collects, ...
... beforehand upped students, grades, study found , THURSDAY, April 1 (HealthDay ... a little more likely? , Perhaps, according to a study ... test depressed college students, grades. , Test-takers who saw the letter ... to do with a grade, scored significantly worse than those who ...
... for women at increased risk , THURSDAY, April 1 (HealthDay News) ... boosts the risk that a woman will develop breast cancer. But ... of cancer in mice with that gene by deactivating another gene. ... 85 percent greater lifetime risk for developing breast cancer than other ...
... hyperthyroidism should have it treated to reduce their ... -- Young adults who have an overactive thyroid face ... the condition, Taiwanese researchers report. , "This is a ... treatment to prevent these complications," Dr. Majaz Moonis, ...
... ... Fekrat of AfghanLord about the situation of opium and heroin addicts within Afghanistan. ... 1.5 million addicts within the country and the capital city of Kabul. ... day. This health crisis is ruining families who do not know the ...
Cached Medicine News:Health News:UMass Memorial health care develops fully integrated EMR 2Health News:Seeing Letter 'F' May Lower Test Scores 2Health News:Overactive Thyroid Linked to Stroke in Young Adults 2Health News:Interview: Heroin Addicts in Afghanistan: An Inside Look 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: